cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1457Research ArticleИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦАCORONARY HEART DISEASEКлинико-фармакоэкономическая оценка ингибиторов ангиотензин-превращающего фермента периндоприла и эналаприла у больных ишемической болезнью сердца, подвергнутых коронарному шунтированиюClinical and pharmaco-economic assessment of ACE inhibitors perindopril and enalapril in coronary heart disease patients after coronary artery bypass graft surgeryЛопатинЮ. М.LopatinYu. M.

Заведующий кафедрой кардиологии с функциональной диагностикой ФУВ

lopatin@vlpost.ruДроноваЕ. П.DronovaE. P.

Врач-кардиолог

Волгоградский государственный медицинский университетVolgograd State Medical UniversityВолгоградский областной кардиологический центрVolgograd Region Cardiology Centre200920062009834753Copyright © Лопатин Ю.М., Дронова Е.П., 20092009Лопатин Ю.М., Дронова Е.П.Lopatin Y.M., Dronova E.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1457Цель

Цель. Дать клинико-фармакоэкономическую оценку длительного применения ингибиторов ангиотензин-превращающего фермента периндоприла и эналаприла у больных ишемической болезнью сердца (ИБС) с коронарным шунтированием (КШ).

Материал и методы

Материал и методы. 250 пациентов с ИБС были включены в открытое, проспективное, рандомизированное, клиническое исследование. I группе больных (n=125) назначали периндоприл, II группе (n=125) — эналаприл. Длительность наблюдения составила 3 года после выполнения КШ. Все больные получали стандартную терапию ИБС.

Результаты

Результаты. По сравнению с эналаприлом для длительного приема периндоприла были характерны: улучшение систолической функции левого желудочка, повышение толерантности к физическим нагрузкам, снижение частоты ишемических эпизодов.

Заключение

Заключение. Назначение периндоприла пациентам с ИБС после КШ по сравнению с эналаприлом имеет очевидные преимущества, в т.ч. с точки зрения более низких материальных затрат на лечение данной категории пациентов.

Aim

Aim. To perform clinical and pharmaco-economic assessment of long-term therapy with ACE inhibitors perindopril and enalapril in coronary heart disease (CHD) patients after coronary artery bypass graft (CABG) surgery.

Material and methods

Material and methods. This prospective, randomized clinical trial included 250 CHD patients. Group I (n=125) received perindopril, Group II (n=125) — enalapril. The follow-up period lasted for three years after CABG inter­vention. All participants received standard CHD therapy.

Results

Results. Comparing to enalapril, perindopril demonstrated improved left ventricular systolic function, increased physical stress tolerance, and reduced frequency of ischemic episodes.

Conclusion

Conclusion. In CHD patients after CABG, perindopril therapy is more clinically efficient and cost-effective than enalapril treatment.

ишемическая болезнь сердцакоронарное шунтированиепериндоприлэналаприлcoronary heart diseasecoronary artery bypass graft surgeryperindoprilenalaprilReferencesSwedberg K, Kjekshus J. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Am J Cardiol 1988; 62: 60A-6.Swedberg K, Kjekshus J. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Am J Cardiol 1988; 62: 60A-6.SOLVD (Studies of Left Ventricular Disfunction) Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive failure. N Engl J Med 1991; 1325: 293-302.SOLVD (Studies of Left Ventricular Disfunction) Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive failure. N Engl J Med 1991; 1325: 293-302.Pfeffer MAA, Braunwald E, Moe LA, et al. (on behalf of the SAVE investigators). Effect of captopril on mortality and morbidity in patients with LVD after myocardial dysfunction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-77.Pfeffer MAA, Braunwald E, Moe LA, et al. (on behalf of the SAVE investigators). Effect of captopril on mortality and morbidity in patients with LVD after myocardial dysfunction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-77.The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8.The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8.Ambrosioni E, Borghi C, Magnani B. for the Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332: 80-5.Ambrosioni E, Borghi C, Magnani B. for the Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332: 80-5.The Heart Outcomes Prevention Evaluation study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.The Heart Outcomes Prevention Evaluation study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.The EUropean trial on Reduction Of cardiac events with Perindopril in patients with stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.The EUropean trial on Reduction Of cardiac events with Perindopril in patients with stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.Cox JL, Chiasson DA, Gotlieb AI. Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis 1991; 34: 45-68.Cox JL, Chiasson DA, Gotlieb AI. Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis 1991; 34: 45-68.Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition and treatment. Circulation 1998; 97: 16-31.Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition and treatment. Circulation 1998; 97: 16-31.Bourassa MG. Fate of venous grafts: the past, the present and the future. JACC 1991; 17: 1081-3.Bourassa MG. Fate of venous grafts: the past, the present and the future. JACC 1991; 17: 1081-3.Sasaki Y, Suehiro S, Becker AE, et al. Role of endothelial denudation and smooth muscle cell differentiation in neointimal formation of human vein grafts after coronary artery bypass grafting: therapeutic implications. J Heart 2000; 83: 69-75.Sasaki Y, Suehiro S, Becker AE, et al. Role of endothelial denudation and smooth muscle cell differentiation in neointimal formation of human vein grafts after coronary artery bypass grafting: therapeutic implications. J Heart 2000; 83: 69-75.Oosterga M, Voors AA, Pinto YM, et al. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). Am J Cardiol 2001; 87: 542-6.Oosterga M, Voors AA, Pinto YM, et al. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). Am J Cardiol 2001; 87: 542-6.Knoller-Hansen L, Steffesnsen R, Grande P. The angiotensinconverting enzyme inhibition post-revascularization study (APRES). JACC 2000; 35: 881-8.Knoller-Hansen L, Steffesnsen R, Grande P. The angiotensinconverting enzyme inhibition post-revascularization study (APRES). JACC 2000; 35: 881-8.Rouleau JL, Warnica WJ, Baillot R, et al. for the IMAGINE (Ischemia Management with Accupril post-bypass Graft via Inhibition of the coNverting Enzyme) Investigators. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation 2008; 117: 24-31.Rouleau JL, Warnica WJ, Baillot R, et al. for the IMAGINE (Ischemia Management with Accupril post-bypass Graft via Inhibition of the coNverting Enzyme) Investigators. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation 2008; 117: 24-31.Lazar HL, Bao Y, Rivers S, et al. Pre-treatment with angiotensin-converting inhibitors attenuates ischemic reperfusion injury during coronary revascularization. Ann Thorac Surg 2002; 73: 1522-7.Lazar HL, Bao Y, Rivers S, et al. Pre-treatment with angiotensin-converting inhibitors attenuates ischemic reperfusion injury during coronary revascularization. Ann Thorac Surg 2002; 73: 1522-7.Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341-81.Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341-81.Диагностика и лечение стабильной стенокардии. Российские рекомендации, второй пересмотр. Кардиоваск тер профил 2008; 7(6): Приложение 4.Диагностика и лечение стабильной стенокардии. Российские рекомендации, второй пересмотр. Кардиоваск тер профил 2008; 7(6): Приложение 4.Lazar HL. All Coronary Artery Bypass Graft Surgery Patients Will Benefit From Angiotensin-Converting Enzyme Inhibitors. Circulation 2008; 117: 6-8.Lazar HL. All Coronary Artery Bypass Graft Surgery Patients Will Benefit From Angiotensin-Converting Enzyme Inhibitors. Circulation 2008; 117: 6-8.

The authors declare that there are no conflicts of interest present.